Table 14.
Genes downregulated between six- and eightfold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects a
Stable vs Con | AE-1 vs Con | AE-3 vs Con | AE-10 vs Con | ||||
---|---|---|---|---|---|---|---|
Fold changes | Genes | Fold changes | Genes | Fold changes | Genes | Fold changes | Genes |
6.0 | NDUFV3 | 6.0 | MAL | 6.0 | IL7R | 6.0 | HKDC1 |
6.0 | C17orf45 | 6.0 | ARHGAP12 | 6.0 | CD28 | 6.1 | TANC2 |
6.1 | MAL | 6.0 | TRAPPC4 | 6.0 | KIR2DS1 | 6.1 | FAM5B |
6.1 | CXCR6 | 6.0 | GNLY | 6.0 | FLJ20647 | 6.2 | KIAA0748 |
6.1 | SUCLA2 | 6.0 | N/A | 6.1 | N/A | 6.3 | CD40LG |
6.1 | C21orf7 | 6.0 | LOC642376 | 6.1 | CLDN1 | 6.3 | PCDH10 |
6.2 | TNPO1 | 6.0 | MYOZ3 | 6.1 | TRBV5-4 | 6.3 | LOC644273 |
6.2 | LOC643514 | 6.1 | FLJ20647 | 6.1 | CARD11 | 6.3 | CD96 |
6.2 | ALS2CR13 | 6.1 | CD96 | 6.1 | LOC441320 | 6.3 | TRA@ |
6.2 | CREB1 | 6.2 | MAL | 6.1 | ACADSB | 6.3 | TRBV3-1 |
6.2 | C17orf45 | 6.2 | GIMAP5 | 6.1 | NXPH4 | 6.4 | TRA@ |
6.3 | NELL2 | 6.2 | CLDN1 | 6.2 | SCNN1D | 6.4 | LOC642483 |
6.3 | C6orf32 | 6.2 | CD3D | 6.2 | MTMR1 | 6.5 | ANKDD1A |
6.3 | LOC642455 | 6.2 | LY9 | 6.2 | MAL | 6.5 | N/A |
6.4 | GMDS | 6.3 | LOC123876 | 6.2 | ZAP70 | 6.5 | N/A |
6.4 | ABHD6 | 6.3 | TNFRSF25 | 6.3 | MAL | 6.5 | LY9 |
6.4 | DAPP1 | 6.3 | C21orf7 | 6.3 | IL2RB | 6.6 | CD8B |
6.4 | SH3BGRL | 6.3 | LOC645885 | 6.3 | EDG8 | 6.6 | MGC26597 |
6.5 | IL7R | 6.3 | BLOC1S3 | 6.3 | HKDC1 | 6.7 | TRBV19 |
6.6 | LOC441601 | 6.3 | LOC644727 | 6.3 | SCAP1 | 6.7 | LOC145783 |
6.6 | GPR18 | 6.4 | CCDC45 | 6.3 | LOC440455 | 6.8 | CD8B |
6.7 | P2RX5 | 6.4 | C21orf7 | 6.3 | CD300E | 6.9 | C21orf7 |
6.7 | LY9 | 6.5 | CD28 | 6.4 | LY9 | 6.9 | UBASH3A |
6.8 | GGPS1 | 6.5 | LOC440455 | 6.4 | KIR2DS2 | 7.0 | LOC400768 |
6.8 | EIF3S6 | 6.5 | IL24 | 6.4 | SLAMF6 | 7.1 | CD8B |
6.8 | ARHGAP15 | 6.5 | GHRL | 6.4 | SAA3P | 7.1 | HAND1 |
6.8 | SF3B1 | 6.5 | FAM113B | 6.4 | SF3A2 | 7.2 | LOC126075 |
6.8 | GPR89A | 6.5 | LOC644663 | 6.5 | UNQ470 | 7.2 | TNFRSF7 |
6.9 | LOC129293 | 6.5 | C15orf37 | 6.5 | C6orf21 | 7.3 | LEF1 |
6.9 | CPNE3 | 6.5 | MAL | 6.6 | CD96 | 7.3 | HLA-DOA |
6.9 | LY9 | 6.5 | LOC644445 | 6.6 | CD244 | 7.4 | LOC646279 |
7.0 | PIP3-E | 6.6 | LOC126075 | 6.6 | N/A | 7.4 | YLPM1 |
7.0 | TAF9 | 6.6 | 1-Sep | 6.6 | KLRK1 | 7.4 | LOC643514 |
7.0 | N/A | 6.6 | UBASH3A | 6.6 | C16orf5 | 7.5 | MTMR1 |
7.0 | KIAA0748 | 6.7 | SAA3P | 6.6 | TRBC1 | 7.6 | NOG |
7.1 | CD55 | 6.8 | CD6 | 6.6 | LOC339778 | 7.7 | TCF7 |
7.2 | EIF3S6 | 6.8 | TRBV5-4 | 6.7 | GNLY | 7.7 | KIAA0748 |
7.2 | PGRMC2 | 6.9 | 1-Sep | 6.7 | LDLRAP1 | 7.7 | C21orf7 |
7.3 | C21orf7 | 6.9 | LOC129293 | 6.8 | HAND1 | 7.7 | PRDM9 |
7.4 | PSMD6 | 7.0 | SCNN1D | 6.8 | CD3D | 7.7 | FCER2 |
7.5 | ABLIM1 | 7.0 | SIT1 | 6.8 | FLJ45825 | 7.9 | CD8B |
7.6 | STAG2 | 7.1 | GATA3 | 6.8 | SF3A2 | 8.0 | LEF1 |
7.8 | CCDC45 | 7.1 | CD7 | 6.8 | CXCR3 | ||
7.8 | UNQ470 | 7.1 | CDKN3 | 6.8 | KIR3DL3 | ||
7.9 | LY9 | 7.2 | SCAP1 | 6.8 | LAT | ||
8.0 | CD40LG | 7.3 | TRA@ | 6.9 | CD52 | ||
7.3 | LY9 | 6.9 | TNFRSF7 | ||||
7.3 | DDAH1 | 6.9 | LOC442726 | ||||
7.3 | TRA@ | 6.9 | 3-Sep | ||||
7.5 | TNFRSF7 | 6.9 | KIAA0748 | ||||
7.5 | KIAA0748 | 6.9 | XG | ||||
7.6 | ITM2A | 6.9 | KIAA1549 | ||||
7.6 | CD5 | 7.0 | RNF157 | ||||
7.6 | D4S234E | 7.0 | SIT1 | ||||
7.6 | CD300E | 7.0 | CD1C | ||||
7.7 | APBB1 | 7.0 | SLC16A10 | ||||
7.8 | CD3D | 7.0 | CD3G | ||||
7.8 | LCK | 7.1 | CD6 | ||||
7.8 | UBASH3A | 7.1 | LY9 | ||||
7.9 | XG | 7.1 | FLT3LG | ||||
7.1 | LOC647353 | ||||||
7.2 | LOC123876 | ||||||
7.2 | CX3CR1 | ||||||
7.2 | LOC126075 | ||||||
7.3 | NELL2 | ||||||
7.4 | LY9 | ||||||
7.4 | MAL | ||||||
7.4 | KIR2DS2 | ||||||
7.4 | CHIA | ||||||
7.4 | BIN1 | ||||||
7.5 | CCDC78 | ||||||
7.5 | MAL | ||||||
7.5 | C21orf7 | ||||||
7.5 | KIR2DL4 | ||||||
7.6 | CD6 | ||||||
7.6 | CD3D | ||||||
7.7 | 1-Sep | ||||||
7.7 | LCK | ||||||
7.8 | ITM2A | ||||||
7.8 | TRA@ | ||||||
7.9 | SIT1 | ||||||
7.9 | CD5 | ||||||
8.0 | CD8A | ||||||
8.0 | LOC129293 |
aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) after the hospital admission, as compared to healthy controls (Con).